Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

October 31, 2013

Conditions
Healthy
Interventions
BIOLOGICAL

hRESCAP

one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)

BIOLOGICAL

Placebo

Trial Locations (1)

2333CL

Centre for Human Drug Research, Leiden

Sponsors
All Listed Sponsors
collaborator

Alloksys Life Sciences B.V.

INDUSTRY

lead

TNO

OTHER

NCT01889147 - Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP) | Biotech Hunter | Biotech Hunter